Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?

Nurix Therapeutics, Inc. (NRIX) shares rallied 6.8% in the last trading session to close at $15.64. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.4% loss over the past four weeks.The stock price movement was observed after it announced a transformative global collaboration with Roche to co-develop and co-commercialize the former’s investigational BTK degrader, bexobrutideg. Investor enthusiasm was driven by the deal’s substantial financial terms, including a $700 million upfront payment and up to $2.3 billion in potential milestone payments, as well as the validation of bexobrutideg’s potential across hematology, immunology and neurology. The partnership also significantly expands the candidate’s development pathway beyond its ongoing pivotal chronic lymphocytic leukemia program into additional B-cell malignancies, multiple sclerosis and chronic spontaneous urticaria. Moreover, the profit-sharing structure in the United States and Roche’s global development and commercialization capabilities strengthen Nurix’s long-term growth prospects while reducing execution risk.This company is expected to post quarterly loss of $0.73 per share in its upcoming report, which represents a year-over-year change of -40.4%. Revenues are expected to be $14.3 million, down 67.5% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For Nurix Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NRIX going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Nurix Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, NovoCure (NVCR), finished the last trading session 1.8% lower at $16.85. NVCR has returned -4.1% over the past month.NovoCure's consensus EPS estimate for the upcoming report has changed -13.7% over the past month to -$0.3. Compared to the company's year-ago EPS, this represents a change of +16.7%. NovoCure currently boasts a Zacks Rank of #3 (Hold).Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks